Hold SHOP you think-? It was like a million dollar insider buy. Shopify Inc. (SHOP)-? NYSE - Nasdaq Real Time Price. 33.08+0.84(+2.62%)
Van or Stoney, Nov 11 AMGN $295 Calls chased from the $2s-$3.5, highest price sold was +$4.50. Is it heading to $300?
Goldman Sachs interested in buying payments technology firm, WSJ reports » 11:55 GS, CCRD Goldman Sachs (GS) is…
Honestly it's going to be tight. My best guess is it could fail to achieve $300- I would take profits.
I don't know why but this Skywater is one of the jumpiest tech stks-- whenver I check it on news it explosively moving one way or theother- SkyWater Technology management to meet with Needham 10:55 SKYT Meeting to be held in Boston on November 16 hosted by Needham. Put that in the ole' date book. Look at this! SKYT SkyWater Technology $11.43 +2.77(+31.99%)<-- WTF
Cassava Sciences price target raised to $12 from $8 at Univest Securities 12:33 SAVA Univest Securities analyst James Jang raised the firm's price target on Cassava Sciences to $12 from $8 and keeps a Sell rating on the shares following the Q3 results. The analyst does not anticipate Cassava will raise additional equity until Q3 of 2028. The company's Phase 3 enrollment is now at over 650 patients, and based on this, full enrollment is likely during Q1 of 2025, with a data release during Q3 of 2026, Jang tells investors in a research note.
Ionis Pharmaceuticals announces data from GSK's Phase 2b study of bepirovirsen 11:03 IONS, GSK Ionis Pharmaceuticals (IONS) announced that GSK (GSK) presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen, an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus. The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen and hepatitis B virus DNA for 24 weeks after end of bepirovirsen treatment in people with CHB. The study results were presented at the American Association for the Study of Liver Diseases' The Liver Meeting in Washington, DC. The results from the B-Clear Phase 2b study provide initial evidence that bepirovirsen, as monotherapy or in combination with nucleoside/nucleotide analogue, can deliver sustained reductions in HBsAg and HBV viral DNA in specific patient groups. The full results from the study are now available in The New England Journal of Medicine. In treatment arm 1 of the study, 9% of patients on NA treatment and 10% of patients not on NA treatment achieved the primary outcome of HBsAg levels below the Lower Limit of Quantification and HBV DNA levels below the LLOQ, respectively. This is defined as a sustained response and was observed for 24 weeks post last dose. In the study, sustained response rates were higher in subjects with low baseline HBsAg than in those with high baseline HBsAg. Patients with low baseline hepatitis B surface antigen levels responded best to treatment with bepirovirsen with 16% and 25% of patients achieving the primary outcome in treatment arm 1 of the on NA and not on NA cohort, respectively. Currently, nucleoside/nucleotide analogues are the recommended first-line therapy for patients with chronic HBV because they can inhibit viral replication. However, they cannot clear the virus and are generally taken for life. Bepirovirsen is uniquely designed to reduce HBV replication and suppress HBsAg and stimulate innate immunity which could potentially lead to functional cure. Functional cure is largely defined as sustained, undetectable levels of HBV DNA and HBsAg in the blood with or without generating protective antibodies after a finite course of treatment. Functional cure occurs when the virus is not eliminated from the body but is at low levels that are undetectable in blood and can be controlled by the immune system without medication. GSK is exploring sequential treatment trials of bepirovirsen with other therapeutic modalities, with the aim of increasing functional cure rate in more patients and reducing the overall burden of CHB. These include Phase 2b study of bepirovirsen in sequential combination with pegylated interferon treatment; Phase 2 study of bepirovirsen in sequential combination with GSK's chronic hepatitis B targeted immunotherapy. IONS-$42
Tesla recalls over 40,000 U.S. vehicles over power steering issue 10:57 TSLA Tesla is voluntarily recalling 40,168 2017-2021 Model S and Model X vehicles that could experience a loss of power steering assist, according to a filing with the National Highway Traffic Administration. Tesla said as of November 1, 97% of the recalled cars have installed an update that addresses the problem and no further action is necessary from those owners.